RT Journal Article
SR Electronic
T1 Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.22.23287597
DO 10.1101/2023.03.22.23287597
A1 An, Zesheng
A1 Zhou, Xian
A1 Li, Yanfeng
A1 Jaquith, Jane
A1 McCarthy-Fruin, Kathleen
A1 Sletten, Jennifer
A1 Warrington, Kenneth J.
A1 Weyand, Cornelia
A1 Crowson, Cynthia S.
A1 Chumsri, Saranya
A1 Knutson, Keith L.
A1 Figueroa-Parra, Gabriel
A1 Sanchez-Rodriguez, Alain
A1 Thanarajasingam, Uma
A1 Duarte-García, Alí
A1 Zeng, Hu
YR 2023
UL http://medrxiv.org/content/early/2023/03/27/2023.03.22.23287597.abstract
AB Objective To evaluate seroreactivity and disease biomarkers after 2 or 3 doses of COVID-19 mRNA vaccines in a cohort of patients with rheumatic diseases.Methods We collected biological samples longitudinally before and after 2-3 doses of COVID-19 mRNA vaccines from a cohort of patients with systemic lupus erythematosus (SLE), psoriatic arthritis, Sjogren’s syndrome, ankylosing spondylitis, and inflammatory myositis. Anti-SARS-CoV-2 spike IgG and IgA and anti-dsDNA concentration were measured by ELISA. A surrogate neutralization assay was utilized to measure antibody neutralization ability. Lupus disease activity was measured by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Expression of type I interferon signature was measured by real-time PCR. The frequency of extrafollicular double negative 2 (DN2) B cells was measured by flow cytometry.Results Most of the patients generated high SARS-CoV-2 spike-specific neutralizing antibodies comparable to those in healthy controls after 2 doses of mRNA vaccines. The antibody level declined over time but recovered after the third dose of the vaccine. Rituximab treatment substantially reduced antibody level and neutralization ability. Among SLE patients, no consistent increase in SLEDAI scores was observed post-vaccination. The changes in anti-dsDNA antibody concentration and expression of type I IFN signature genes were highly variable but did not show consistent or significant increases. Frequency of DN2 B cells remained largely stable.Conclusion Rheumatic disease patients without rituximab treatment have robust antibody responses toward COVID-19 mRNA vaccination. Disease activity and disease-associated biomarkers remain largely stable over 3 doses of vaccines, suggesting that COVID-19 mRNA vaccines may not exacerbate rheumatic diseases.KEY MESSAGESPatients with rheumatic diseases mount robust humoral immunity towards 3 doses of COVID-19 mRNA vaccines.Disease activity and biomarkers remain stable following 3 doses of COVID-19 mRNA vaccines.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04839315Funding StatementThis study was funded by National Institute of Arthritis and Musculoskeletal and Skin Disease, NIH (grant AR-077518), the National Institute of Allergy and Infectious Diseases, NIH (grant AI-162678) and Mayo Foundation for Medical Education and ResearchAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has been approved by Institutional Review Board of Mayo Clinic Rochester (IRB 21-000501). Written informed consent was obtained from all participating patients.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors